Fig. 3: Rate of grade 2+ gastrointestinal hemorrhage stratified by rs1478947 genotype and treatment arm.

The rate of gastrointestinal hemorrhage (from time of treatment initiation to treatment end, up to 2 years) was 33.3% (13/39) and 6.2% (17/275) in bevacizumab-treated patients with the AA/AG and GG genotypes, respectively, while the incidence in the placebo arm was 2.9% (1/35) and 1.9% (5/267). Because of the low MAF, only one patient carried the AA genotype. This patient was randomized to receive bevacizumab and experienced a grade 3 gastrointestinal hemorrhage during cycle 3, which resulted in removal from study treatment.